top of page
EsoGuard patient.png

Detect altered DNA 

With over 90% sensitivity and specificity at detecting BE and EAC, the EsoGuard esophageal DNA test allows detection of these conditions in a simple office-based procedure WITHOUT endoscopy.

1

408

patient human study

published in
Science Translational Medicine

1

>90%

sensitivity & specificity

at detecting BE, with and without dysplasia, as
well as esophageal adenocarcinoma

1

iStock-155145178.jpg

EsoGuard analyzes methylation at

31 sites on 2 genes

1

A test that goes down easy

​

Barrett’s esophagus is a premalignant condition of the distal esophagus that increases the risk of esophageal cancer. Unfortunately, screening for Barrett’s esophagus currently requires endoscopy, an invasive and expensive procedure, and thus, it is not routinely performed. Moinova et al. have now demonstrated a simplified approach to screening by identifying a pair of DNA methylation markers that correlate with the presence of Barrett’s esophagus. The authors also invented a swallowable balloon-based device that can capture DNA samples for methylation analysis and found that it is well tolerated in patients and provides >90% sensitivity and specificity compared to endoscopy, suggesting its potential as a screening method.

​

Science Translational Medicine  17 Jan 2018:
Vol. 10, Issue 424, eaao5848
DOI: 10.1126/scitranslmed.aao5848

How it works

Distal esophageal cells are sampled in a simple office-based procedure, shipped in preservative with the provided mailer, and processed at our laboratory. Results are typically available within 3 weeks.

01

Cell Collection

​

Distal esophageal cells are sampled in a simple office-based procedure and sent to our laboratory. 

EsoGuard_collection.png

02

Test

​

The EsoGuard Esophageal DNA Test assesses signature epigenetic changes indicative of BE and EAC using advanced molecular diagnostic techniques.

EsoGuard Test.png

03

Results

​

The physician receives a report with a positive or negative result indicating whether or not epigenetic changes consistent with BE/EAC were detected.

​

EsoGuard Results.png
Meet the team behind the test

Researchers, Physicians, Scientists, Innovators, Educators

EsoGuard arose from a collaboration among faculty at Case Western Reserve University, including a renowned cancer geneticist, a passionate gastroenterologist and a dedicated pathologist.
Markowitz.jpg

SANDY MARKOWITZ, MD

Physician, Department of Hematology and Oncology

​

Ingalls Professor of Cancer Genetics, Department of Medicine, School of Medicine

​

Professor, Department of Genetics and Genome Sciences, School of Medicine

​

Professor, Department of Molecular Biology and Microbiology, School of Medicine

​

Principal Investigator, Case GI SPORE, Case Comprehensive Cancer Center

 

Co-Leader, GI Cancer Genetics

Program, Case Comprehensive Cancer Center

​

Case Western Reserve University

University Hospitals Cleveland Medical Center

Chak_Amitabh.jpg

AMITABH CHAK, MD

Physician, Department of Gastroenterology, University Hospitals Cleveland Medical Center

​

Professor, Department of Medicine, School of Medicine

​

Member, Cancer Genomics and Epigenomics Program, Case Comprehensive Cancer Center

​

Case Western Reserve University

University Hospitals Cleveland
Medical Center

Willis.jpg

JOE WILLIS, MD

Vice Chairman of Pathology, Clinical Affairs, Laboratory Director, University Hospitals Cleveland Medical Center

​

Professor, Department of Pathology, School of Medicine

​

Member, Cancer Genomics and Epigenomics Program, Case Comprehensive Cancer Center

​

Case Western Reserve University

University Hospitals Cleveland
Medical Center

Ready to start screening with EsoGuard?

Incorporating EsoGuard in your practice is easy. Reach out today and we'll get you started. 

REFERENCES: 

1. Science Translational Medicine 17 Jan 2018: Vol. 10, Issue 424, eaao5848, DOI: 10.1126/scitranslmed.aao5848 

bottom of page